Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse
neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract …

This review covers the diverse topic of neuroendocrine neoplasms (NENs), a relatively rare
and heterogeneous tumor type, comprising~ 2% of all malignancies, with a prevalence of< …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …

Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …

Background Effective systemic therapies for patients with advanced, progressive
neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess …

M. Pavel a D. O'Toole b F. Costa c J. Capdevila d D. Gross e R. Kianmanesh f E. Krenning g
U. Knigge h R. Salazar i U.-F. Pape a K. Öberg j all other Vienna Consensus Conference …

The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …

Background Somatostatin analogues are commonly used to treat symptoms associated with
hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects …

The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and …